Expertise
Genvissa connects the decisions that determine whether a technology becomes a credible product, an investable business and a solution that healthcare can adopt.
The standard entry point for an operating medtech business. A structured, evidence-based review identifies maturity, critical blockers, conflicting assumptions and the decisions that deserve immediate attention.
Translate technical capability into a product that is clear enough to design, test, regulate, manufacture, fund and sell. This work aligns the unmet need, intended use, claims and development priorities.
Build proportionate foundations that support safe development and credible claims. Genvissa keeps regulatory, quality and evidence strategy aligned, and adds qualified specialists where formal depth is required.
One integrated plan from current state to launch and adoption. The blueprint brings product, evidence, regulatory, quality, manufacturing, market access, finance and governance into a single controlled critical path.
Regulatory approval does not create adoption. This work identifies who uses, pays, benefits and blocks, then shapes the evidence, economics, pilot and commercial route around a real pathway.
Continuing senior capability for businesses that need more than periodic advice. Engagements can cover CTO, CSO, COO or programme-director responsibilities with a defined remit and board-level accountability.
Independent support when a programme is delayed, underfunded, poorly controlled or no longer aligned to a credible product. The focus is containment, truth and an executable recovery path.
Decision-focused scrutiny before or after investment, acquisition or licensing. Genvissa tests the technical and operating reality behind the narrative and identifies practical value-creation priorities.
How we deliver
The work is scaled to the consequence of the decision, with stronger evidence, competence checks and independent review where risk is higher.
Fit, urgency, authority, budget, competence and conflicts.
Evidence, constraints, dependencies and decision consequences.
Outcome, scope, assumptions, exclusions and acceptance.
Controlled work products, decisions, actions and milestones.
Risk-based review and cross-functional consistency checks.
Ownership, unresolved actions and the next-stage roadmap.
What stood out was the combination of senior strategic judgement and practical delivery. Genvissa did not stop at recommendations. They translated the discussion into a clear plan, defined decisions and work our team could act on immediately.
Ways to start
Pre-read, a focused working session and a concise decision note for a founder, academic or executive facing one important choice.
A structured review, risk map and 90-day plan when the need is to understand the whole picture before committing further time or capital.
A bounded programme designed around a specific milestone, readiness decision, recovery need or route-to-market challenge.
Not sure where to begin?
A short conversation is usually enough to identify the right entry point and whether Genvissa can add value.